Patients undergoing maintenance hemodialysis continue to experience disproportionately high mortality and substantial treatment-related burden. Among the modifiable aspects of dialysis care, treatment duration represents a potentially powerful yet underused lever …
Brief Report: Prevalence and Economic Burden of Chronic Conditions in the Commercially Insured US Population (2024) Overview A 2024 analysis conducted by FAIR Health presents new data regarding the epidemiology …
Key takeaways: Using NHANES data from 2017 to 2023, obesity prevalence in the U.S. is 75.2% when excess adiposity cutoffs are used. Among adults with a BMI of less …
โ๏ธ ADMIN EDIT MODE local_hospital MedJournal dark_mode Research chevron_right Immunology Targeted Immunotherapy in Chronic Autoimmune Disorders A comprehensive analysis of novel monoclonal antibody treatments and their long-term efficacy in Phase …
y
Login/Sign Up – MedResearch Pro MedResearch Pro Research Pricing About Log In Sign Up menu Welcome to MedResearch Pro Join thousands of medical professionals advancing their knowledge. Continue with Google …
Login/Sign Up – MedResearch Pro MedResearch Pro Research Pricing About Log In Sign Up menu Welcome to MedResearch Pro Join thousands of medical professionals advancing their knowledge. Continue with Google …
Excerpt:
The FDA has granted approval to Novartis for Itvisma (onasemnogene abeparvovec-brve), the first gene replacement therapy for spinal muscular atrophy (SMA) available for patients aged 2 years and older. Backed by data from the Phase 3 STEER and Phase 3b STRENGTH trials, this one-time intrathecal treatment addresses the genetic root cause of SMA and is expected to be available in the U.S. this December.
